Format

Send to

Choose Destination
Cytokine. 2012 Oct;60(1):1-12. doi: 10.1016/j.cyto.2012.06.018. Epub 2012 Jul 4.

Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes.

Author information

1
Department of Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawaii, 651 Ilalo Street BSB 222, Honolulu, HI 96813, USA. junchen@hawaii.edu

Abstract

Monocyte Chemoattractant Protein-1 (MCP-1) is the first discovered and most extensively studied CC chemokine, and the amount of studies on its role in the etiologies of obesity- and diabetes-related diseases have increased exponentially during the past two decades. This review attempted to provide a panoramic perspective of the history, regulatory mechanisms, functions, and therapeutic strategies of this chemokine. The highlights of this review include the roles of MCP-1 in the development of obesity, diabetes, cardiovascular diseases, insulitis, diabetic nephropathy, and diabetic retinopathy. Therapies that specifically or non-specifically inhibit MCP-1 overproduction have been summarized.

PMID:
22766373
PMCID:
PMC3437929
DOI:
10.1016/j.cyto.2012.06.018
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center